Treating NSCLC With Nintedanib

Chandra P. Belani, MD, Deputy Director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses the VEGF-targeted agent nintedanib (BIBF 1120).

Clinical Pearls:

• Nintedanib was studied in combination with docetaxel in a phase III randomized study of NSCLC
• This study showed an improvement in progression-free survival
• In a second trial, in combination with pemetrexed, nintedanib showed no benefit to progression-free survival